Skip to the content Skip to the main menu
ShroomStocks.ca

Investing is a trip

  • Featured Content
  • Mushrooms
  • Psychedelics
  • Psilocybin
  • Microdosing
  • Media

Top Posts & Pages

  • Absolem Health signs a mushroom extraction deal
    Absolem Health signs a mushroom extraction deal
  • We downloaded RLOVE, a dating app for psychonauts and "light warriors." Here's what happened
    We downloaded RLOVE, a dating app for psychonauts and "light warriors." Here's what happened
  • Mydecine Innovations (MYCO.NE) files patent for MDMA-like compounds
    Mydecine Innovations (MYCO.NE) files patent for MDMA-like compounds
  • Red Light Holland (TRIP.C) turns to virtual reality to inform customers about psychedelics
    Red Light Holland (TRIP.C) turns to virtual reality to inform customers about psychedelics
  • Red Light Holland (TRIP.C) throws a logo redesign party with Russell Peters and Khloe Terae
    Red Light Holland (TRIP.C) throws a logo redesign party with Russell Peters and Khloe Terae

Recent Posts

  • Numinus Wellness (NUMI.T) Highlights Key Milestones in MAPS-Sponsored Clinical Trial
  • Mydecine’s (MYCO.NEO) to collaborate with The Newly Institute for psychedelic assisted therapy
  • Mydecine’s (MYCO.NEO) to collaborate with The Newly Institute for psychedelic assisted therapy
  • Filament Health (FH.NE) Hovers Above Record Lows After Announcing Licensing Agreement with Cybin Therapeutics
  • Revive Therapeutics (RVV.C) and a psilocybin trial-test progress update
  • Revive Therapeutics (RVV.C) and a psilocybin trial-test progress update
  • Numinus Wellness (NUMI.T) Submits CTA for HOPE Phase 1 Study
  • What does Health Canada’s amendment proposal mean for psychedelics? – another sector roundup
  • What does Health Canada’s amendment proposal mean for psychedelics? – another sector roundup
  • MYND Life Sciences (MYND.C) provides unorthodox route to better mental health
  • Chart Attack: MYND Life Sciences (MYND.CN) Double Bottom Reversal Watch as Psychedelics Continue to Bleed
  • Filament Health Corp. (FH.NE) Receives Health Canada Approval for Phase 2 Clinical Trial
  • About

Investing is a trip

  • Home
  • Posts

Top Posts & Pages

  • Absolem Health signs a mushroom extraction deal
    Absolem Health signs a mushroom extraction deal
  • We downloaded RLOVE, a dating app for psychonauts and "light warriors." Here's what happened
    We downloaded RLOVE, a dating app for psychonauts and "light warriors." Here's what happened
  • Mydecine Innovations (MYCO.NE) files patent for MDMA-like compounds
    Mydecine Innovations (MYCO.NE) files patent for MDMA-like compounds
  • Red Light Holland (TRIP.C) turns to virtual reality to inform customers about psychedelics
    Red Light Holland (TRIP.C) turns to virtual reality to inform customers about psychedelics
  • Red Light Holland (TRIP.C) throws a logo redesign party with Russell Peters and Khloe Terae
    Red Light Holland (TRIP.C) throws a logo redesign party with Russell Peters and Khloe Terae

Recent Posts

  • Numinus Wellness (NUMI.T) Highlights Key Milestones in MAPS-Sponsored Clinical Trial
  • Mydecine’s (MYCO.NEO) to collaborate with The Newly Institute for psychedelic assisted therapy
  • Mydecine’s (MYCO.NEO) to collaborate with The Newly Institute for psychedelic assisted therapy
  • Filament Health (FH.NE) Hovers Above Record Lows After Announcing Licensing Agreement with Cybin Therapeutics
  • Revive Therapeutics (RVV.C) and a psilocybin trial-test progress update
  • Revive Therapeutics (RVV.C) and a psilocybin trial-test progress update
  • Numinus Wellness (NUMI.T) Submits CTA for HOPE Phase 1 Study
  • What does Health Canada’s amendment proposal mean for psychedelics? – another sector roundup
  • What does Health Canada’s amendment proposal mean for psychedelics? – another sector roundup
  • MYND Life Sciences (MYND.C) provides unorthodox route to better mental health
  • Chart Attack: MYND Life Sciences (MYND.CN) Double Bottom Reversal Watch as Psychedelics Continue to Bleed
  • Filament Health Corp. (FH.NE) Receives Health Canada Approval for Phase 2 Clinical Trial
  • About
Fallback image

Revive Therapeutics (RVV.C) and a psilocybin trial-test progress update

  • Post date
    January 17, 2022
  • Posted by
    Joseph
  • Posted in Mushrooms, PharmaTher, PHRM.C, psilcocybin, Psychedelics, Revive Therapeutics, RVV.C, thin strip technology, University of Health Sciences Antigua
  • Comments
    0
Fallback image

Numinus Wellness (NUMI.T) Submits CTA for HOPE Phase 1 Study

  • Post date
    January 14, 2022
  • Posted by
    Kieran Robertson
  • Posted in clinical trial, clinical trials psilocybin 2021, Mushrooms, NBIO-01, NUMI.T, Numinus Health, numinus stock, Numinus Wellness Inc., Numinus Wellness Inc. (NUMI.T), Patent, Patent Application, patent pending, process technology, psilocybin, psychedelic-assisted psychotherapies, Psychedelics
  • Comments
    0
Fallback image

What does Health Canada’s amendment proposal mean for psychedelics? – another sector roundup

  • Post date
    January 14, 2022
  • Posted by
    GaalenEngen
  • Posted in Health Canada restricted drug amendments, Health Science, Mushrooms, Psychedelics, psychedelics stocks 2022, Sector Roundup, who is the best psychedelics stock to invest in Canada
  • Comments
    0
Fallback image

What does Health Canada’s amendment proposal mean for psychedelics? – another sector roundup

  • Post date
    January 14, 2022
  • Posted by
    GaalenEngen
  • Posted in Health Canada restricted drug amendments, Health Science, Mushrooms, Psychedelics, psychedelics stocks 2022, Sector Roundup, who is the best psychedelics stock to invest in Canada
  • Comments
    0
Fallback image

MYND Life Sciences (MYND.C) provides unorthodox route to better mental health

  • Post date
    January 12, 2022
  • Posted by
    Joseph
  • Posted in Alzheimer's, cybin, CYBN.E, field trip, Major depressive disorder, mental health, Mind Medicine, Mushrooms, MYCO.T, MYND Life Sciences, MYND.C, NUMI.T, Psychedelics, Today's Idea
  • Comments
    0

Nothing more to load.

← Previous Page Next Page →

Theme by Anders Norén